DeStefano David sold $82K of VERX (indirect holdings)

DeStefano David sold 6,460 indirectly-held shares of Vertex, Inc. (VERX) at $12.75 on 2026-05-28.

Original reporting
SEC EDGAR · DeStefano David
Published Jun 1, 2026, 8:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 1, 2026, 8:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$VERX
Neutral
medium confidence
Mentioned
$VERX
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$VERXNeutralLow
01

Why it matters

Traders may treat the disclosure as a minor sentiment datapoint; without accompanying operational news, it should not be weighted like a fundamental update.

02

Market read

Primarily a sentiment/positioning signal; limited incremental information for valuation.

03

What to watch

No 10b5-1 plan is indicated, but the filing alone doesn’t reveal intent, tax timing, or whether other insiders are buying/selling concurrently.

Relevance 6/10Novelty 3/10Timing: After-hours/filing disclosure on 2026-06-01 (SEC Form 4 filed 16:17:29 ET).

Background

The article summarizes an SEC Form 4 insider transaction for Vertex, Inc., showing a director’s open-market sale.

Company-level read

Ticker impact

$VERXNeutralMedium confidence
Context

Vertex director David DeStefano sold 6,460 shares in an open-market transaction totaling $82,365, disclosed via SEC Form 4.

Expected impact

Low near-term impact; any move is likely limited to intraday sentiment around the filing.

Evidence & confidence

The filing is an ownership-change disclosure with no stated new company event (no earnings, trial, deal, or guidance). The sale size is relatively small versus typical market capitalization, and there is no 10b5-1 plan stated.

Market effects

Minimal; this is company-specific insider activity without sector-wide read-through.

None expected beyond US biotech/healthcare sentiment.

None expected.

Counterpoint

The sale may be routine liquidity management (and could be consistent with non-informational motives), so price reaction may be overstated.

Key entities

  • Vertex, Inc.

    Public company whose director reported an open-market sale of shares via SEC Form 4.

  • David DeStefano

    Director who sold 6,460 shares at $12.75/share (total $82,365).

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$VERXMed

Needham raises Vertex stock price target on strong Q3 results

Needham raised its price target on Vertex Inc. (VERX) to $30 from $20, citing strong Q3 results. Revenue beat estimates by 1.7%, and adjusted EBITDA surpassed forecasts by 15%. Q4 guidance was mixed, with revenue lowered but EBITDA raised. DA Davidson also raised its target to $16, noting cloud growth. Vertex's Q3 earnings exceeded expectations, with adjusted EPS of $0.26 and revenue of $213.3M. The company raised its full-year outlook, citing stronger margins and e-invoicing demand.

$VERXMed

DA Davidson raises Vertex stock price target on cloud growth

DA Davidson raised its price target on Vertex Inc. (NASDAQ:VERX) to $16 from $12, citing strong Q3 2026 earnings and accelerated cloud growth. The company increased its fiscal 2026 cloud growth guidance to 19%. Vertex's stock is trading at $15.92 with a P/E ratio of 735, and it has gained 7% over the past week. The company reported adjusted earnings of $0.26 per share, beating estimates, and revenue of $213.3 million, also exceeding forecasts.

$VERXMed

Vertex Inc (VERX) Q3 2026 Earnings Call Highlights: Revenue Tops Guidance as Cloud

Vertex Inc (VERX) reported Q3 2026 revenue above guidance, but faces challenges including a $1M revenue impact from a lost OEM and potential deceleration in e-invoicing growth. Q4 adjusted EBITDA margins are expected to decline to $58-60M due to marketing expenses. CEO Christopher Young highlighted strong e-invoicing growth and expansion opportunities, while CFO John Schwab noted durable margin improvements and targeted reinvestments.

$VERXMed

What Vertex (VERX) Said on Its Q3 Earnings Call

Vertex (VERX) raised its full-year revenue forecast to $828.9M-$830.9M and adjusted EBITDA to $217.9M-$219.9M. Q4 revenue is expected at $215M-$217M. E-invoicing revenue grew over 100% YoY, driven by France's mandate and Brinta's contribution. Vertex introduced AI-powered tax solutions and repurchased $27M in shares Q3.